Lindsay Robert M, Nesrallah Gihad, Suri Rita, Garg Amit, Moist Louise
Optimal Dialysis Research Unit, London Health Sciences Center and The University of Western Ontario, 800 Commissioners Road East, London, Ontario, Canada N64 4G5.
Curr Opin Nephrol Hypertens. 2004 Nov;13(6):631-5. doi: 10.1097/00041552-200411000-00008.
The HEMO study results have shown that increasing dialysis dose in conventional thrice weekly hemodialysis does not improve patient outcomes. Interest has therefore turned to more frequent (daily) hemodialysis treatments. This review covers the rationale for such an approach together with a current review of the published study data.
Recent studies have suggested improvements in a number of intermediate patient outcomes such as cardiovascular (blood pressure control, left ventricular hypertrophy), anemia, phosphate control, nutritional status and quality of life. Some of these outcomes are associated with increased survival in the dialysis population.
The inference from these studies is that more frequent hemodialysis will indeed reduce mortality and morbidity. To date, however, the studies have all been small and underpowered to detect such primary outcomes. No randomized controlled trials are yet reported. The US National Institutes of Health have sponsored larger scale North American based studies and an International Registry of Daily Dialysis patients has been created to attain further information of the possible benefits of such therapy. In spite of the paucity of hard evidence the studies to date have been enough to convince some jurisdictions to recognize and fund daily hemodialysis treatments.
血液透析(HEMO)研究结果表明,在传统的每周三次血液透析中增加透析剂量并不能改善患者预后。因此,人们的兴趣转向了更频繁(每日)的血液透析治疗。本综述涵盖了这种治疗方法的理论依据以及对已发表研究数据的最新综述。
近期研究表明,在一些中间患者预后指标方面有所改善,如心血管方面(血压控制、左心室肥厚)、贫血、磷控制、营养状况和生活质量。其中一些预后指标与透析人群生存率的提高有关。
这些研究得出的结论是,更频繁的血液透析确实会降低死亡率和发病率。然而,迄今为止,所有研究规模都较小,检测此类主要预后指标的能力不足。尚无随机对照试验的报告。美国国立卫生研究院资助了基于北美的更大规模研究,并创建了每日透析患者国际登记处,以获取有关这种治疗可能益处的更多信息。尽管确凿证据匮乏,但迄今为止的研究已足以说服一些司法管辖区认可并资助每日血液透析治疗。